{"transactions":[{"id":314840,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:10:03.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":3328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026."}],"balance_after":34477,"source":{"system":"sec-edgar","filing":"0000875320-26-000010","document":"wk-form4_1769461800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000010/wk-form4_1769461800.xml","form_type":"4"}},{"id":314839,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:10:03.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026."}],"balance_after":31149,"source":{"system":"sec-edgar","filing":"0000875320-26-000010","document":"wk-form4_1769461800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000010/wk-form4_1769461800.xml","form_type":"4"}},{"id":322127,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-05-19T21:07:43.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":52,"price":424.69,"value":22083.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":23281,"source":{"system":"sec-edgar","filing":"0000875320-25-000201","document":"wk-form4_1747688856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000201/wk-form4_1747688856.xml","form_type":"4"}},{"id":323937,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-17T20:09:02.000Z","date":"2025-03-13","kind":"sale","planned":true,"acquired":false,"shares":3231,"price":510,"value":1647810.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":23281,"source":{"system":"sec-edgar","filing":"0000875320-25-000152","document":"wk-form4_1742242135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000152/wk-form4_1742242135.xml","form_type":"4"}},{"id":324120,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:08:19.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":3231,"price":500,"value":1615500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":26512,"source":{"system":"sec-edgar","filing":"0000875320-25-000144","document":"wk-form4_1741810093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000144/wk-form4_1741810093.xml","form_type":"4"}},{"id":324570,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:08:20.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":3231,"price":490,"value":1583190.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":29743,"source":{"system":"sec-edgar","filing":"0000875320-25-000139","document":"wk-form4_1741208889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000139/wk-form4_1741208889.xml","form_type":"4"}},{"id":325028,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-28T21:23:32.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":1272,"price":480,"value":610560.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":32974,"source":{"system":"sec-edgar","filing":"0000875320-25-000120","document":"wk-form4_1740777806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000120/wk-form4_1740777806.xml","form_type":"4"}},{"id":325027,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-28T21:23:32.000Z","date":"2025-02-26","kind":"tax_withholding","planned":true,"acquired":false,"shares":5954,"price":479.61,"value":2855597.94,"ownership":{"direct":true},"balance_after":34246,"source":{"system":"sec-edgar","filing":"0000875320-25-000120","document":"wk-form4_1740777806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000120/wk-form4_1740777806.xml","form_type":"4"}},{"id":325185,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-26T21:04:53.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":848,"price":480.95,"value":407845.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":40200,"source":{"system":"sec-edgar","filing":"0000875320-25-000101","document":"wk-form4_1740603887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000101/wk-form4_1740603887.xml","form_type":"4"}},{"id":325184,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-26T21:04:53.000Z","date":"2025-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":3971,"price":483.28,"value":1919104.88,"ownership":{"direct":true},"balance_after":41048,"source":{"system":"sec-edgar","filing":"0000875320-25-000101","document":"wk-form4_1740603887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000101/wk-form4_1740603887.xml","form_type":"4"}},{"id":325391,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:07:40.000Z","date":"2025-02-20","kind":"sale","planned":true,"acquired":false,"shares":1111,"price":480,"value":533280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":45019,"source":{"system":"sec-edgar","filing":"0000875320-25-000099","document":"wk-form4_1740431255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000099/wk-form4_1740431255.xml","form_type":"4"}},{"id":325791,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:19:52.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2293,"price":463.46,"value":1062713.78,"ownership":{"direct":true},"balance_after":46130,"source":{"system":"sec-edgar","filing":"0000875320-25-000077","document":"wk-form4_1739999985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000077/wk-form4_1739999985.xml","form_type":"4"}},{"id":326074,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:03:29.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":5324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":48423,"source":{"system":"sec-edgar","filing":"0000875320-25-000055","document":"wk-form4_1739567001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000055/wk-form4_1739567001.xml","form_type":"4"}},{"id":326178,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-12T21:21:16.000Z","date":"2025-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2142,"price":467.98,"value":1002413.16,"ownership":{"direct":true},"balance_after":43099,"source":{"system":"sec-edgar","filing":"0000875320-25-000031","document":"wk-form4_1739395266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000031/wk-form4_1739395266.xml","form_type":"4"}},{"id":326563,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:07:47.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":7114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":45241,"source":{"system":"sec-edgar","filing":"0000875320-25-000005","document":"wk-form4_1738876056.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000005/wk-form4_1738876056.xml","form_type":"4"}},{"id":326562,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:07:47.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":12314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025."}],"balance_after":38127,"source":{"system":"sec-edgar","filing":"0000875320-25-000005","document":"wk-form4_1738876056.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000005/wk-form4_1738876056.xml","form_type":"4"}},{"id":329223,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-11-19T21:08:57.000Z","date":"2024-11-15","kind":"sale","planned":true,"acquired":false,"shares":15,"price":478.56,"value":7178.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024."}],"balance_after":25813,"source":{"system":"sec-edgar","filing":"0000875320-24-000229","document":"wk-form4_1732050530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000229/wk-form4_1732050530.xml","form_type":"4"}},{"id":333649,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-17T20:22:10.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":54,"price":430.93,"value":23270.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr.  Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":25813,"source":{"system":"sec-edgar","filing":"0000875320-24-000150","document":"wk-form4_1715977306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000150/wk-form4_1715977306.xml","form_type":"4"}},{"id":339131,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-27T21:24:03.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":4239,"price":425.7,"value":1804542.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":25813,"source":{"system":"sec-edgar","filing":"0000875320-24-000095","document":"wk-form4_1709069025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000095/wk-form4_1709069025.xml","form_type":"4"}},{"id":339130,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-27T21:24:03.000Z","date":"2024-02-23","kind":"tax_withholding","planned":true,"acquired":false,"shares":3970,"price":431.79,"value":1714206.3,"ownership":{"direct":true},"balance_after":30052,"source":{"system":"sec-edgar","filing":"0000875320-24-000095","document":"wk-form4_1709069025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000095/wk-form4_1709069025.xml","form_type":"4"}},{"id":339402,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-23T21:10:15.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":3002,"price":421.77,"value":1266153.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":34022,"source":{"system":"sec-edgar","filing":"0000875320-24-000085","document":"wk-form4_1708722602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000085/wk-form4_1708722602.xml","form_type":"4"}},{"id":339704,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-21T21:13:37.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":4002,"price":420.79,"value":1684001.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":37024,"source":{"system":"sec-edgar","filing":"0000875320-24-000066","document":"wk-form4_1708549975.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000066/wk-form4_1708549975.xml","form_type":"4"}},{"id":339703,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-21T21:13:37.000Z","date":"2024-02-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":2812,"price":420.58,"value":1182670.96,"ownership":{"direct":true},"balance_after":41026,"source":{"system":"sec-edgar","filing":"0000875320-24-000066","document":"wk-form4_1708549975.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000066/wk-form4_1708549975.xml","form_type":"4"}},{"id":339702,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-21T21:13:37.000Z","date":"2024-02-16","kind":"tax_withholding","planned":true,"acquired":false,"shares":3750,"price":424.01,"value":1590037.5,"ownership":{"direct":true},"balance_after":43838,"source":{"system":"sec-edgar","filing":"0000875320-24-000066","document":"wk-form4_1708549975.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000066/wk-form4_1708549975.xml","form_type":"4"}},{"id":340504,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-13T21:46:04.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":3145,"price":420.24,"value":1321654.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":47588,"source":{"system":"sec-edgar","filing":"0000875320-24-000039","document":"wk-form4_1707860733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000039/wk-form4_1707860733.xml","form_type":"4"}},{"id":340503,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-13T21:46:04.000Z","date":"2024-02-09","kind":"tax_withholding","planned":true,"acquired":false,"shares":2099,"price":422.74,"value":887331.26,"ownership":{"direct":true},"balance_after":50733,"source":{"system":"sec-edgar","filing":"0000875320-24-000039","document":"wk-form4_1707860733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000039/wk-form4_1707860733.xml","form_type":"4"}},{"id":341090,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-08T21:10:13.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":7114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":52832,"source":{"system":"sec-edgar","filing":"0000875320-24-000014","document":"wk-form4_1707426599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000014/wk-form4_1707426599.xml","form_type":"4"}},{"id":341089,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-08T21:10:13.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":45718,"source":{"system":"sec-edgar","filing":"0000875320-24-000014","document":"wk-form4_1707426599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000014/wk-form4_1707426599.xml","form_type":"4"}},{"id":341088,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2024-02-08T21:10:13.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":5814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024."}],"balance_after":37852,"source":{"system":"sec-edgar","filing":"0000875320-24-000014","document":"wk-form4_1707426599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000014/wk-form4_1707426599.xml","form_type":"4"}},{"id":344375,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-11-17T21:11:06.000Z","date":"2023-11-15","kind":"sale","planned":true,"acquired":false,"shares":19,"price":369.92,"value":7028.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":32038,"source":{"system":"sec-edgar","filing":"0000875320-23-000039","document":"wk-form4_1700255434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000039/wk-form4_1700255434.xml","form_type":"4"}},{"id":346668,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-08-11T20:05:13.000Z","date":"2023-08-09","kind":"sale","planned":true,"acquired":false,"shares":63,"price":345.51,"value":21767.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023."}],"balance_after":32038,"source":{"system":"sec-edgar","filing":"0000899243-23-018044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924323018044/doc4.xml","form_type":"4"}},{"id":352342,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-28T21:40:33.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":302,"price":289.6,"value":87459.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $289.60 (range $289.49 to $289.65)."}],"balance_after":32038,"source":{"system":"sec-edgar","filing":"0001209191-23-013685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013685/doc4.xml","form_type":"4"}},{"id":352341,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-28T21:40:33.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":300,"price":288.74,"value":86622.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $288.74 (range $288.42 to $289.37)."}],"balance_after":32340,"source":{"system":"sec-edgar","filing":"0001209191-23-013685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013685/doc4.xml","form_type":"4"}},{"id":352340,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-28T21:40:33.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":3636,"price":287.23,"value":1044368.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.80 to $287.72)."}],"balance_after":32640,"source":{"system":"sec-edgar","filing":"0001209191-23-013685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013685/doc4.xml","form_type":"4"}},{"id":352339,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-28T21:40:33.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":3970,"price":289.12,"value":1147806.4,"ownership":{"direct":true},"balance_after":36276,"source":{"system":"sec-edgar","filing":"0001209191-23-013685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013685/doc4.xml","form_type":"4"}},{"id":352902,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-22T21:25:25.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":900,"price":294.73,"value":265257.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $294.73 (range $294.47 to $295.37)."}],"balance_after":40246,"source":{"system":"sec-edgar","filing":"0001209191-23-011655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011655/doc4.xml","form_type":"4"}},{"id":352901,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-22T21:25:25.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":1843,"price":294.03,"value":541897.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $294.03 (range $293.45 to $294.42)."}],"balance_after":41146,"source":{"system":"sec-edgar","filing":"0001209191-23-011655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011655/doc4.xml","form_type":"4"}},{"id":352900,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-22T21:25:25.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":1223,"price":292.76,"value":358045.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $292.76 (range $292.25 to $293.12)."}],"balance_after":42989,"source":{"system":"sec-edgar","filing":"0001209191-23-011655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011655/doc4.xml","form_type":"4"}},{"id":352899,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-22T21:25:25.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":36,"price":291.01,"value":10476.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."}],"balance_after":44212,"source":{"system":"sec-edgar","filing":"0001209191-23-011655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011655/doc4.xml","form_type":"4"}},{"id":352898,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-22T21:25:25.000Z","date":"2023-02-17","kind":"tax_withholding","acquired":false,"shares":3750,"price":292.85,"value":1098187.5,"ownership":{"direct":true},"balance_after":44248,"source":{"system":"sec-edgar","filing":"0001209191-23-011655","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123011655/doc4.xml","form_type":"4"}},{"id":353278,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-16T21:11:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":308,"price":301.02,"value":92714.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $301.02 (range $300.79 to $301.22)."}],"balance_after":47998,"source":{"system":"sec-edgar","filing":"0001209191-23-010045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010045/doc4.xml","form_type":"4"}},{"id":353277,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-16T21:11:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":1888,"price":300.11,"value":566607.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $300.11 (range $299.76 to $300.70)."}],"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001209191-23-010045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010045/doc4.xml","form_type":"4"}},{"id":353276,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-16T21:11:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":2165,"price":299.08,"value":647508.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $299.08 (range $298.71 to $299.54)."}],"balance_after":50194,"source":{"system":"sec-edgar","filing":"0001209191-23-010045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010045/doc4.xml","form_type":"4"}},{"id":353275,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-16T21:11:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":395,"price":297.97,"value":117698.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $297.97 (range $297.50 to $298.35)."}],"balance_after":52359,"source":{"system":"sec-edgar","filing":"0001209191-23-010045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010045/doc4.xml","form_type":"4"}},{"id":353274,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-16T21:11:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":842,"price":296.85,"value":249947.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.42 to $297.37)."}],"balance_after":52754,"source":{"system":"sec-edgar","filing":"0001209191-23-010045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010045/doc4.xml","form_type":"4"}},{"id":353273,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-16T21:11:01.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":800,"price":295.79,"value":236632.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $295.79 (range $295.31 to $296.12)."}],"balance_after":53596,"source":{"system":"sec-edgar","filing":"0001209191-23-010045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123010045/doc4.xml","form_type":"4"}},{"id":353544,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-14T21:49:25.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":500,"price":300.23,"value":150115.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $300.23 (range $299.96 to $300.63)."}],"balance_after":54396,"source":{"system":"sec-edgar","filing":"0001209191-23-009174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009174/doc4.xml","form_type":"4"}},{"id":353543,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-14T21:49:25.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":1893,"price":299.36,"value":566688.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $299.36 (range $298.86 to $299.83)."}],"balance_after":54896,"source":{"system":"sec-edgar","filing":"0001209191-23-009174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009174/doc4.xml","form_type":"4"}},{"id":353542,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-14T21:49:25.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":2160,"price":298.47,"value":644695.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $298.47 (range $297.85 to $298.82)."}],"balance_after":56789,"source":{"system":"sec-edgar","filing":"0001209191-23-009174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009174/doc4.xml","form_type":"4"}},{"id":353541,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-14T21:49:25.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":245,"price":296.44,"value":72627.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57)."}],"balance_after":58949,"source":{"system":"sec-edgar","filing":"0001209191-23-009174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009174/doc4.xml","form_type":"4"}},{"id":353540,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-14T21:49:25.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":5990,"price":298.26,"value":1786577.4,"ownership":{"direct":true},"balance_after":59194,"source":{"system":"sec-edgar","filing":"0001209191-23-009174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009174/doc4.xml","form_type":"4"}},{"id":353539,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-14T21:49:25.000Z","date":"2023-02-10","kind":"tax_withholding","acquired":false,"shares":3461,"price":294.33,"value":1018676.13,"ownership":{"direct":true},"balance_after":65184,"source":{"system":"sec-edgar","filing":"0001209191-23-009174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009174/doc4.xml","form_type":"4"}},{"id":353970,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"exercise","acquired":false,"shares":1304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":1304},"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353969,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":153,"price":309.06,"value":47286.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $309.06 (range $308.76 to $309.42)."}],"balance_after":68645,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353968,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":620,"price":306.7,"value":190154.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $306.70 (range $306.32 to $307.25)."}],"balance_after":68798,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353967,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":349,"price":305.08,"value":106472.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $305.08 (range $304.72 to $305.43)."}],"balance_after":69418,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353966,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":100,"price":303.64,"value":30364.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $303.64 (range $303.37 to $304.27)."}],"balance_after":69767,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353965,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":70,"price":302,"value":21140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."}],"balance_after":69867,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353964,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"sale","acquired":false,"shares":12,"price":300.39,"value":3604.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."}],"balance_after":69937,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":353963,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-08T21:53:50.000Z","date":"2023-02-06","kind":"exercise","acquired":true,"shares":1304,"price":187.53,"value":244539.12,"ownership":{"direct":true},"balance_after":69949,"source":{"system":"sec-edgar","filing":"0001209191-23-007827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123007827/doc4.xml","form_type":"4"}},{"id":354167,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-03T21:30:03.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":7866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":68645,"source":{"system":"sec-edgar","filing":"0001209191-23-006869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006869/doc4.xml","form_type":"4"}},{"id":354166,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-03T21:30:03.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":12314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023."}],"balance_after":60779,"source":{"system":"sec-edgar","filing":"0001209191-23-006869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006869/doc4.xml","form_type":"4"}},{"id":354165,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2023-02-03T21:30:03.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":12388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023."}],"balance_after":48465,"source":{"system":"sec-edgar","filing":"0001209191-23-006869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006869/doc4.xml","form_type":"4"}},{"id":356513,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-17T21:08:51.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":34,"price":308.61,"value":10492.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."}],"balance_after":36077,"source":{"system":"sec-edgar","filing":"0000899243-22-036184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322036184/doc4.xml","form_type":"4"}},{"id":356786,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"exercise","acquired":false,"shares":1303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option vests in 16 quarterly installments from 2/6/2019."}],"balance_after":1304,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":1303},"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356785,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":83,"price":306.57,"value":25445.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22)."}],"balance_after":36077,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356784,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":140,"price":305.39,"value":42754.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39)."}],"balance_after":36160,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356783,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":280,"price":304.58,"value":85282.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91)."}],"balance_after":36300,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356782,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":261,"price":303.21,"value":79137.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45)."}],"balance_after":36580,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356781,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":189,"price":301.99,"value":57076.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20)."}],"balance_after":36841,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356780,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":210,"price":300.96,"value":63201.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18)."}],"balance_after":37030,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356779,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":140,"price":299.72,"value":41960.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97)."}],"balance_after":37240,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":356778,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-11-09T21:40:50.000Z","date":"2022-11-07","kind":"exercise","acquired":true,"shares":1303,"price":187.53,"value":244351.59,"ownership":{"direct":true},"balance_after":37380,"source":{"system":"sec-edgar","filing":"0000899243-22-035443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322035443/doc4.xml","form_type":"4"}},{"id":358929,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"exercise","acquired":false,"shares":1304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in 16 quarterly installments from 2/6/2019."}],"balance_after":2607,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":1304},"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":358928,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":146,"price":295.14,"value":43090.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $295.14 (range $294.74 to $295.53)."}],"balance_after":36077,"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":358927,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":302,"price":293.99,"value":88784.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $293.99 (range $293.58 to $294.26)."}],"balance_after":36223,"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":358926,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":210,"price":293.02,"value":61534.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $293.02 (range $292.41 to $293.36)."}],"balance_after":36525,"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":358925,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":424,"price":291.53,"value":123608.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $291.53 (range $291.06 to $291.91)."}],"balance_after":36735,"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":358924,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":222,"price":290.32,"value":64451.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $290.32 (range $290.05 to $290.64)."}],"balance_after":37159,"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":358923,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-08-10T20:06:06.000Z","date":"2022-08-08","kind":"exercise","acquired":true,"shares":1304,"price":187.53,"value":244539.12,"ownership":{"direct":true},"balance_after":37381,"source":{"system":"sec-edgar","filing":"0000899243-22-028246","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322028246/doc4.xml","form_type":"4"}},{"id":359511,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"exercise","acquired":false,"shares":7338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":155.57,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":7338},"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359510,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"exercise","acquired":false,"shares":10427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in 16 quarterly installments from 2/6/2019."}],"balance_after":3911,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":10427},"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359509,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":6604,"price":289.48,"value":1911725.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $289.48 (range $289.11 to $290.06)."}],"balance_after":36077,"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359508,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":5737,"price":288.67,"value":1656099.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $288.67 (range $288.11 to $289.09)."}],"balance_after":42681,"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359507,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":4561,"price":287.83,"value":1312792.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10)."}],"balance_after":48418,"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359506,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":963,"price":286.72,"value":276111.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01)."}],"balance_after":52979,"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359505,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"exercise","acquired":true,"shares":7338,"price":155.57,"value":1141572.66,"ownership":{"direct":true},"balance_after":53942,"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":359504,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-07-21T20:48:41.000Z","date":"2022-07-19","kind":"exercise","acquired":true,"shares":10427,"price":187.53,"value":1955375.31,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 100 shares previously purchased under the issuer's Employee Stock Purchase Plan."}],"balance_after":46604,"source":{"system":"sec-edgar","filing":"0000899243-22-026486","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026486/doc4.xml","form_type":"4"}},{"id":365019,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-28T22:18:06.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":560,"price":232.68,"value":130300.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $232.68 (range $232.43 to $232.87)."}],"balance_after":36077,"source":{"system":"sec-edgar","filing":"0000899243-22-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008109/doc4.xml","form_type":"4"}},{"id":365018,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-28T22:18:06.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":2784,"price":231.64,"value":644885.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $231.64 (range $231.08 to $232.07)."}],"balance_after":36637,"source":{"system":"sec-edgar","filing":"0000899243-22-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008109/doc4.xml","form_type":"4"}},{"id":365017,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-28T22:18:06.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":3188,"price":230.62,"value":735216.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $230.62 (range $230.07 to $231.05)."}],"balance_after":39421,"source":{"system":"sec-edgar","filing":"0000899243-22-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008109/doc4.xml","form_type":"4"}},{"id":365016,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-28T22:18:06.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":1040,"price":229.41,"value":238586.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $229.41 (range $228.91 to $229.81)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":42609,"source":{"system":"sec-edgar","filing":"0000899243-22-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008109/doc4.xml","form_type":"4"}},{"id":365015,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-28T22:18:06.000Z","date":"2022-02-24","kind":"tax_withholding","acquired":false,"shares":6038,"price":227.86,"value":1375818.68,"ownership":{"direct":true},"balance_after":43649,"source":{"system":"sec-edgar","filing":"0000899243-22-008109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008109/doc4.xml","form_type":"4"}},{"id":365571,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-22T21:51:08.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":1038,"price":233.27,"value":242134.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $233.27 (range $232.91 to $233.50)."}],"balance_after":49687,"source":{"system":"sec-edgar","filing":"0000899243-22-007203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007203/doc4.xml","form_type":"4"}},{"id":365570,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-22T21:51:08.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":600,"price":231.85,"value":139110.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $231.85 (range $231.67 to $232.01)."}],"balance_after":50725,"source":{"system":"sec-edgar","filing":"0000899243-22-007203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007203/doc4.xml","form_type":"4"}},{"id":365569,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-22T21:51:08.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":385,"price":231.01,"value":88938.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $231.01 (range $230.66 to $231.43)."}],"balance_after":51325,"source":{"system":"sec-edgar","filing":"0000899243-22-007203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007203/doc4.xml","form_type":"4"}},{"id":365568,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-22T21:51:08.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":1303,"price":230.05,"value":299755.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $230.05 (range $229.65 to $230.59)."}],"balance_after":51710,"source":{"system":"sec-edgar","filing":"0000899243-22-007203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007203/doc4.xml","form_type":"4"}},{"id":365567,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-22T21:51:08.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":986,"price":229.22,"value":226010.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $229.22 (range $228.65 to $229.60)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":53013,"source":{"system":"sec-edgar","filing":"0000899243-22-007203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007203/doc4.xml","form_type":"4"}},{"id":365566,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-22T21:51:08.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":3439,"price":232.51,"value":799601.89,"ownership":{"direct":true},"balance_after":53999,"source":{"system":"sec-edgar","filing":"0000899243-22-007203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007203/doc4.xml","form_type":"4"}},{"id":365916,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":15000,"kind":"person","name":"ALTSHULER DAVID","position":1,"cik":"0001550395","reported_name":"ALTSHULER DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Global Research and CSO"}}],"security":"Common Stock","published_at":"2022-02-16T21:05:57.000Z","date":"2022-02-14","kind":"sale","acquired":false,"shares":2444,"price":232.02,"value":567056.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $232.02 (range $231.82 to $232.60)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":57438,"source":{"system":"sec-edgar","filing":"0001209191-22-010175","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122010175/doc4.xml","form_type":"4"}}],"next_cursor":"2022-02-16T21:05:57.000000Z,365916"}